News update via NF Bot

Colorectal cancer survivor Todd Hoffman came to UT MD Anderson when Ohio oncologists couldn’t provide the complex surgery he needed. Today, he is cancer-free and back to living a full life after a total pelvic exenteration (TPE).

Background Pelvic exenteration (PE) is a radical surgical option for locally advanced or recurrent gynecologic cancers, but its contemporary risk–benefit profile has never been systematically compared with the original Brunschwig experience. The purpose of the study was to quantify changes in major postoperative morbidity, perioperative mortality, and oncologic outcomes after PE between Brunschwig-era series (1954–1969) and contemporary series (1990–2024). Materials and Methods This was an International Prospective Register of Systematic Reviews (PROSPERO)-registered (CRD420251009209) systematic review and meta-analysis. PubMed/MEDLINE, Web of Science, and Scopus were searched through December 2024 for studies reporting complications, mortality, or survival after pelvic exenteration for gynecologic malignancies. Two reviewers independently performed study selection and data extraction. Major morbidity was harmonized to Clavien–Dindo grade III or higher (or equivalent). Random-effects meta-analyses were performed where appropriate. All eligible studies identified were retrospective series. Results A total of 34 studies (5478 patients; 913 historical and 4565 contemporary) were included. Major morbidity decreased from 58% (95% CI 46–68%) in historical series to 23% (95% CI 17–31%) in contemporary series, while perioperative mortality declined from 23 (95% CI 17–30%) to 3% (95% CI 2–4%). Contemporary series also reported improved oncologic outcomes, although heterogeneity and differences in follow-up precluded direct survival comparisons. Conclusions Compared with the original Brunschwig era, contemporary pelvic exenteration is associated with substantially lower major morbidity and perioperative mortality, together with improved oncologic outcomes. These findings illustrate the remarkable technical and conceptual evolution of pelvic exenteration over the past seven decades, although direct comparisons between historical and contemporary series should be interpreted cautiously because of differences in patient selection and clinical practice over time.

The historical evolution of globe-preserving management provides important context for interpreting contemporary outcomes in lacrimal gland carcinoma. Since the early 1990s, evidence has challenged the assumption that orbit-sacrificing surgery, including cranio-orbital resection and orbital exenteration, confers a survival advantage. This was subsequently reinforced by more contemporary long-term comparative outcome data demonstrating no significant survival benefit over globe-preserving surgery with radiotherapy. Recent findings in lacrimal gland adenoid cystic carcinoma are broadly consistent with this established evidence base, although comparisons with exenteration remain susceptible to treatment-selection bias.

What is a total pelvic exenteration? Colorectal surgical oncologist George Chang, M.D., answers this and eight other questions.

Check this out! Listen now on @Spotify.

Check this out! Listen now on @Spotify.

YouTube video by MAGEFA

Check this out! Listen now on @Spotify.

Pelvic exenteration (PE) is a therapeutic option for patients with cervical cancer who have undergone concurrent chemoradiotherapy (CCRT) but subsequently

This study investigated the use of personalized three-dimensional (3D) models as a decision-making aid for patients undergoing pelvic exenteration for comp

In this longitudinal study of 273 patients undergoing pelvic exenteration between 2008 and 2014, one-third survived beyond 10 years with median overall sur

Empty pelvis syndrome is identified as the single most frequent cause of major morbidity after pelvic exenteration. A syndrome pattern in the natural histo

Total pelvic exenteration (TPE) offers the possibility of long-term survival for select patients with locally advanced and recurrent pelvic malignancies an